Synapse - Patients with AML and an IDH2-R172 mutation exhibit a unique response to intensive induction chemotherapy, suggesting futility of mid-cycle bone marrow biopsy and caution when considering re-induction

Patients with AML and an IDH2-R172 mutation exhibit a unique response to intensive induction chemotherapy, suggesting futility of mid-cycle bone marrow biopsy and caution when considering re-induction Meeting Abstract

Authors:	Yisraeli Salman, M.; Terry, A. R.; Derkach, A.; Nemirovsky, D.; Chin, K. K.; Valtis, Y. K.; Boussi, L.; Spivey, T.; Xiao, W.; Famulare, C.; Ciervo, J.; Rowe, J. M.; Tallman, M. S.; Stein, E. M.
Abstract Title:	Patients with AML and an IDH2-R172 mutation exhibit a unique response to intensive induction chemotherapy, suggesting futility of mid-cycle bone marrow biopsy and caution when considering re-induction
Meeting Title:	66th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	144
Issue:	Suppl. 1
Meeting Dates:	2024 Dec 7-10
Meeting Location:	San Deigo, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2024-11-05
Start Page:	2847
End Page:	2848
Language:	English
ACCESSION:	WOS:001422229700036
DOI:	10.1182/blood-2024-193242
PROVIDER:	wos
Notes:	Meeting Abstract -- Hybrid event -- Source: Wos